Cipla shares surged 4.08% to Rs 1,407 on Monday, claiming the top spot on the Nifty 50. The trigger: Citi is reiterating its Buy and putting the stock on a 90-day positive catalyst watch, flagging a near-term sequence of US approvals and domestic recovery that the brokerage believes can meaningfully re-rate the stock. Citi’s target remains Rs 1,700, that is 26% upside from where the stock closed.
The timing is notable. Cipla just delivered one of its weakest quarterly prints in years, and multiple brokerages are still leaning bullish.
Key Takeaways
Cipla shares jumped 4.08% to Rs 1,407, topping Nifty 50 on June 22, 2026. Citi reiterates Buy with Rs 1,700 target, a 26% upside from the current price.
Stock placed on Citi’s 90-day positive catalyst watch. gVentolin launch (H1 FY27) and gFlovent approval are the two critical US triggers.
The Indore (Pithampur) facility is still under OAI; the reinspection outcome is the single biggest binary risk. Cipla’s India respiratory segment grew 15% YoY in Q4 FY26; the One-India business crossed the Rs 12,500 crore annual milestone.
US Business Is the Whole Thesis
Citi’s call is a US recovery bet, plain and simple.
Cipla secured USFDA approval for Albuterol Sulfate Inhalation Aerosol (90 mcg), the first AB-rated generic equivalent of Ventolin HFA, manufactured at the company’s new US facility, with launch planned for H1 FY27.
According to IQVIA data, the total US albuterol market stands at approximately $1.5 billion. ICICI Securities expects gVentolin and gOfev (Nintedanib generic) combined to generate roughly $100 million in annual sales.
Citi separately flags a potential gFlovent approval as an additional trigger, Cipla’s generic of the widely prescribed fluticasone propionate inhaler. No PDUFA date or ANDA confirmation has been disclosed publicly; timeline remains unconfirmed.
Cipla US Pipeline: Key Triggers
| Product | Reference Brand | US Market Size | Status |
|---|---|---|---|
| gVentolin (Albuterol 90 mcg) | Ventolin HFA (GSK) | ~$1.5 Bn | USFDA Approved; H1 FY27 Launch |
| gNintedanib (Ofev generic) | Ofev (Boehringer) | ~$3.76 Bn | Approved and Launched |
| gFlovent | Flovent HFA (GSK) | Significant | Pending — Timeline Unconfirmed |
| gAdvair / gSymbicort | Advair / Symbicort | Multi-Bn | 6–12 month pipeline |
Sources: IQVIA MAT January–February 2026; ICICI Securities; Cipla Q4 FY26 Press Release
Q4 Numbers Were Ugly. That Is Kind of the Point.
Cipla posted its highest-ever annual revenue at Rs 28,163 crore for FY26, though the US business logged $780 million, supported by demand in the differentiated portfolio. The quarterly story was less flattering. Revenue from operations came in at Rs 6,541 crore against Rs 6,729 crore a year ago. Net profit fell 55% to Rs 554.6 crore, and EBITDA contracted 38% to Rs 955 crore, margin collapsed to 14.6% from 22.8%.
For the full year, EBITDA margin came in at 21% versus the company’s own guidance of 24%. That is a 300 basis point miss, not trivial.
The culprit is largely known: gRevlimid exclusivity loss, Lanreotide supply disruption, and legacy regulatory issues at Indian plants. Citi’s argument is these are rearview-mirror problems. Nuvama Institutional Equities upgraded the stock to Buy from Reduce and raised its target 21% to Rs 1,550, citing margin and capex commentary and upcoming complex launches.
FY25 vs FY26 Snapshot
| Metric | FY25 | FY26 | Change |
|---|---|---|---|
| Revenue (Rs Cr) | 27,548 | 28,163 | +2.2% |
| Net Profit (Rs Cr) | 5,269 | 3,862 | –26.7% |
| EBITDA Margin | 25.9% | 21.0% | –490 bps |
| US Revenue | ~$900 Mn | $780 Mn | –13% |
| EPS (Basic, Rs) | 65.29 | 48.03 | –26.4% |
| Final Dividend | — | Rs 13/share | FY26 |
Sources: Cipla Q4 FY26 Press Release; ICICI Direct; Groww Research
Check Live: Cipla Option Chain (CIPLA) — Live OI, IV, Greeks & PCR
Domestic Side: Not Getting Enough Credit
Oddly, the India story has been overshadowed by the US noise. Cipla’s One-India business crossed the Rs 12,500 crore annual revenue milestone in FY26, with Q4 FY26 India quarterly sales growing 15% year-on-year to Rs 3,007 crore. Respiratory, urology, anti-diabetes, and cardiac therapies all delivered double-digit branded prescription growth.
Citi flagged domestic respiratory recovery as a watch item. Cipla’s respiratory franchise is the core identity of the business, both here and in the US. A synchronised upturn in both geographies would directly expand EBITDA margins, and management expects EBITDA margins to improve every quarter in FY27, with stronger profitability in H2 driven by key US launches.
R&D spending for Q4 FY26 stood at Rs 509 crore, or 7.8% of quarterly sales, elevated, but consistent with building the pipeline that the Citi thesis depends on.
Regulatory Front: Goa Clean, Indore Still Open
USFDA classified Cipla’s Verna, Goa facility as Voluntary Action Indicated after a routine GMP and Pre-Approval Inspection in April 2026. Bommasandra (Bengaluru), Sitec (Navi Mumbai), and Medispray (Goa) also received VAI or NAI classifications during FY26.
What remains unresolved is Pithampur, Indore. Cipla received a USFDA warning letter dated November 17, 2023 for GMP violations at the Pithampur facility. The warning letter does not halt sales of existing products but puts a hold on new product approvals from the site.
The OAI classification at Pithampur was communicated in August 2023, with Cipla stating it does not see material risk to its existing commercial product portfolio and that it is executing a de-risking plan. Reinspection remains awaited, and resolution would unlock the pending ANDA pipeline from that site.
USFDA Facility Compliance Tracker
| Facility | Inspection Status | Outcome |
|---|---|---|
| Verna, Goa | Inspected April 2026 | VAI âś… |
| Bommasandra, Bengaluru | FY26 | VAI âś… |
| Sitec, Navi Mumbai | FY26 | NAI âś… |
| Medispray, Goa | FY26 | VAI âś… |
| Pithampur, Indore | OAI (Aug 2023); Warning Letter (Nov 2023) | Reinspection Awaited ⏳ |
Sources: Cipla regulatory filings; BSE disclosures; Business Standard
Valuation: 25x Forward, Citi Still Says Buy
Cipla currently trades at 25x FY27E and 21x FY28E earnings. For reference, Sun Pharma trades at 25–28x forward P/E; Dr. Reddy’s, at 20–23x. Cipla’s multiple is broadly sector-in-line, which means the re-rating case depends entirely on earnings delivery, not valuation expansion.
Management targets $1 billion in US sales for FY27, recovering from $780 million in FY26. Brokerages have set targets as high as Rs 1,700 (Citi), with consensus ranging from Rs 1,550 to Rs 1,700. ICICI Securities raised FY27/FY28 EPS estimates post-results, reflecting confidence in the gVentolin and gOfev contributions.
The key question is whether gVentolin can achieve 60–70% of the $100 million consensus in its first full year of launch; if it does, the FY27 earnings recovery trajectory shifts materially.
NiftyTrader’s Verdict
Cipla is a “bad quarter, turning story” setup, with an ugly near-term print and building forward triggers. The Indore reinspection is the single biggest binary risk; a clean outcome unlocks pending ANDAs and changes the US revenue ramp timeline.
For the stock to justify 25x FY27E, which is broadly peer-level, Cipla needs at least gVentolin to ramp on schedule and One-India to sustain double-digit growth. Citi thinks that combination is probable within 90 days. Indore is the variable that could derail or accelerate that call. Track it.
Check live: Cipla’s live price, option chain, and institutional flows on NiftyTrader’s
Option Chain Tool and FII-DII Dashboard.
FAQ
Q1. Why did Cipla’s Q4 FY26 net profit fall 55% despite record annual revenue?
Net profit fell to Rs 554.6 crore in Q4 FY26. The primary drivers were the loss of gRevlimid exclusivity in the US market, Lanreotide supply disruption after the Pharmathen OAI classification by USFDA in February 2026, and higher total expenses which rose to Rs 5,982 crore from Rs 5,514 crore a year ago. Full-year EBITDA margin of 21% missed the company’s own 24% guidance by 300 basis points.
Q2. What is the current status of Cipla’s Indore (Pithampur) facility — is it still under USFDA OAI?
Yes. The Pithampur facility received OAI classification from USFDA in August 2023, followed by a Warning Letter in November 2023 for GMP violations. The warning letter blocks new product approvals from that site but does not affect existing commercial products. A reinspection outcome has not been announced as of June 22, 2026. Resolution would materially expand Cipla’s pending ANDA pipeline from the facility.
Q3. How strong is Cipla’s balance sheet despite the earnings decline?
Cipla reported a net cash position of Rs 10,526 crore as of March 31, 2026, providing substantial headroom for R&D spending (Rs 509 crore in Q4 alone, at 7.8% of quarterly sales), pipeline launches, and potential acquisitions.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Please consult a SEBI-registered investment advisor before making any investment decisions. Equity investments are subject to market risk.
Â
